In a recent STEP-HFpEF trial, once-weekly semaglutide treatment in obese, non-diabetic HFpEF patients for 52 weeks reduced HF-related symptoms, body weight, and NT-proBNP levels as well as improved physical and exercise function and 6-min walk distance.164,165 However, the effects of semaglutide on cardiac hemodynamics were not assessed in this study. The gene discussed is NPPB; the disease is hydrops fetalis.